Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.
Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, Huang X, Monian P, Jiang X, de Stanchina E, Baselga J, Liu N, Chandarlapaty S, Rosen N. Will M, et al. Among authors: chandarlapaty s. Cancer Discov. 2014 Mar;4(3):334-47. doi: 10.1158/2159-8290.CD-13-0611. Epub 2014 Jan 16. Cancer Discov. 2014. PMID: 24436048 Free PMC article.
Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast Cancer.
Mai N, Dos Anjos CH, Razavi P, Safonov A, Patil S, Chen Y, Drago JZ, Modi S, Bromberg JF, Dang CT, Liu D, Norton L, Robson M, Chandarlapaty S, Jhaveri K. Mai N, et al. Among authors: chandarlapaty s. Res Sq [Preprint]. 2024 May 2:rs.3.rs-4237867. doi: 10.21203/rs.3.rs-4237867/v1. Res Sq. 2024. Update in: NPJ Breast Cancer. 2024 Oct 18;10(1):92. doi: 10.1038/s41523-024-00699-3 PMID: 38746324 Free PMC article. Updated. Preprint.
Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
Peters S, Loi S, André F, Chandarlapaty S, Felip E, Finn SP, Jänne PA, Kerr KM, Munzone E, Passaro A, Pérol M, Smit EF, Swanton C, Viale G, Stahel RA. Peters S, et al. Among authors: chandarlapaty s. Ann Oncol. 2024 Jul;35(7):607-629. doi: 10.1016/j.annonc.2024.04.002. Epub 2024 Apr 20. Ann Oncol. 2024. PMID: 38648979 Review.
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.
Scaltriti M, Chandarlapaty S, Prudkin L, Aura C, Jimenez J, Angelini PD, Sánchez G, Guzman M, Parra JL, Ellis C, Gagnon R, Koehler M, Gomez H, Geyer C, Cameron D, Arribas J, Rosen N, Baselga J. Scaltriti M, et al. Among authors: chandarlapaty s. Clin Cancer Res. 2010 May 1;16(9):2688-95. doi: 10.1158/1078-0432.CCR-09-3407. Epub 2010 Apr 20. Clin Cancer Res. 2010. PMID: 20406840 Free PMC article.
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.
Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J. Serra V, et al. Among authors: chandarlapaty s. Oncogene. 2011 Jun 2;30(22):2547-57. doi: 10.1038/onc.2010.626. Epub 2011 Jan 31. Oncogene. 2011. PMID: 21278786 Free PMC article.
156 results